Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPOSE trial of 177Lu-edotreotide versus best standard of care in aggressive well-differentiated GEP-NETs
2021-001086-20Phase 3Completed
- Sponsor
- ITM Isotope Technologies Munich
- Start
- May 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing 177Lu-edotreotide with Best standard of care (2 arms). Primary endpoint: Progression-free survival. Started May 2021; status: completed.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2021-001086-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001086-20.